Q-omics provides the consensus-scored MRPS30-DT profile across patient tissues and cancer cell-line models. MRPS30-DT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, MRPS30-DT is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, MRPS30-DT RNA expression shows 19,375 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KICH, and UVM as cancer lineages where MRPS30-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS30-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS30-DT survival associations across molecular data types. MRPS30-DT RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS30-DT RNA expression–survival associations across cancer types. High MRPS30-DT expression shows unfavorable associations in UVM, KICH, UCEC and LIHC, but favorable associations in BRCA and SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for MRPS30-DT RNA expression.
This table summarizes MRPS30-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MRPS30-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS30-DT shows lower tumor expression in KICH, THCA, KIRC, UCEC and BLCA and higher tumor expression in HNSC. The KICH box plot shows higher MRPS30-DT RNA expression in normal versus tumor tissue (log2 FC = −1.555, t-test p < 0.001).
This table shows molecular features associated with MRPS30-DT in patient tissues and cancer cell lines. In patient samples, MRPS30-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
